Research ArticleArticle
Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action
M. E. Bradley, B. Dombrecht, J. Manini, J. Willis, D. Vlerick, S. De Taeye, K. Van den Heede, A. Roobrouck, E. Grot, T. C. Kent, T. Laeremans, S. Steffensen, G. Van Heeke, Z. Brown, S. J. Charlton and K. D. Cromie
Molecular Pharmacology February 2015, 87 (2) 251-262; DOI: https://doi.org/10.1124/mol.114.094821
M. E. Bradley
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
B. Dombrecht
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
J. Manini
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
J. Willis
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
D. Vlerick
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
S. De Taeye
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
K. Van den Heede
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
A. Roobrouck
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
E. Grot
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
T. C. Kent
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
T. Laeremans
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
S. Steffensen
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
G. Van Heeke
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
Z. Brown
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
S. J. Charlton
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
K. D. Cromie
Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Inhibition of CXCR2 Signaling by Biparatopic Nanobodies
M. E. Bradley, B. Dombrecht, J. Manini, J. Willis, D. Vlerick, S. De Taeye, K. Van den Heede, A. Roobrouck, E. Grot, T. C. Kent, T. Laeremans, S. Steffensen, G. Van Heeke, Z. Brown, S. J. Charlton and K. D. Cromie
Molecular Pharmacology February 1, 2015, 87 (2) 251-262; DOI: https://doi.org/10.1124/mol.114.094821
Research ArticleArticle
Inhibition of CXCR2 Signaling by Biparatopic Nanobodies
M. E. Bradley, B. Dombrecht, J. Manini, J. Willis, D. Vlerick, S. De Taeye, K. Van den Heede, A. Roobrouck, E. Grot, T. C. Kent, T. Laeremans, S. Steffensen, G. Van Heeke, Z. Brown, S. J. Charlton and K. D. Cromie
Molecular Pharmacology February 1, 2015, 87 (2) 251-262; DOI: https://doi.org/10.1124/mol.114.094821
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement